(NASDAQ: CRNX) Crinetics Pharmaceuticals's forecast annual revenue growth rate of 529.38% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.2%.
Crinetics Pharmaceuticals's revenue in 2025 is $760,000.On average, 8 Wall Street analysts forecast CRNX's revenue for 2025 to be $452,287,668, with the lowest CRNX revenue forecast at $131,152,182, and the highest CRNX revenue forecast at $855,767,988. On average, 8 Wall Street analysts forecast CRNX's revenue for 2026 to be $4,274,155,931, with the lowest CRNX revenue forecast at $2,585,571,588, and the highest CRNX revenue forecast at $10,190,805,582.
In 2027, CRNX is forecast to generate $20,839,051,238 in revenue, with the lowest revenue forecast at $11,770,908,335 and the highest revenue forecast at $30,444,168,647.